Yervoy Approval History
FDA Approved: Yes (First approved March 25, 2011)
Brand name: Yervoy
Generic name: ipilimumab
Dosage form: Injection
Company: Bristol-Myers Squibb
Treatment for: Melanoma, Metastatic, Renal Cell Carcinoma, Colorectal Cancer
Yervoy (ipilimumab) is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of melanoma. Yervoy is also used in combination with Opdivo (nivolumab) for the treatment of advanced renal cell carcinoma, and microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.
Development History and FDA Approval Process for Yervoy
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.